Kornimate/medical-research-clean huggingface dataset:
the artificial saliva spray reduces xerostomia in diabetes type ii

Conditions: Xerostomia Due to Hyposecretion of Salivary Gland; Diabetes Mellitus, Type 2

Summary: in diabetes type ii the xerostomia is a quite frequent symptom. in evaluating the activity of an artificial saliva spray compared to a water gel in patients with diabetes type ii patients had to follow a three day treatment with each product. whereas after the first treatment period the two groups had to follow a wash out period of three days before the second treatment period could begin. the artificial saliva spray reduced the xerostomia and the inflammation or the oral tissue.

in diabetes type ii the xerostomia is a quite frequent symptom. the trial was conducted at a single center. designed and implementing uni en iso 14155:2012, strobe statement version 4 and was in conformity with the guidelines of the declaration of helsinki. the type of study was a randomized, cross over clinical trial to compare two treatments (artificial saliva spray (aldiamed(r) mouth spray) as vs. (tonimer(r) throat spray) tt . twenty one subjects that were part of the epidemiological screening for asymptomatic vascular diseases conducted in the irwin lab3 of spoltore (pe / italy) the degree of xerostomia for the admission had to be at least \> 2 according to a semi-quantal scale (ranging from 0 to 6) and patients already under treatment for xerostomia or with xerostomia score \< 2, suffering from obesity, cancer, drug addiction or alcoholism were excluded. the patients had to follow a three day treatment with each product. whereas after the first treatment period the two groups had to follow a wash out period of three days before the second treatment period could begin. the study consisted of a preliminary selection during screening, the measurement of xerostomia and random allocation, first treatment period, wash out period and finally the second treatment period.

Eligibility criteria:
inclusion criteria: * suffering xerostomia * degree of xerostomia at least \> 2 according to a semiquantal scare ranging from 0 to 6 * diabetes type ii \> one year, with stabilized oral hypoglycemic therapy from at least 6 months. * concomitant chronic diseases pertaining to dyslipidemia, cardiovascular and/or gastrointestinal diseases, and anxiety/depression were accepted provided under adequate therapy since at least 6 months. exclusion criteria: * under treatment for xerostomia or with xerostomia score \< 2 * suffering from obesity (bmi \> 30 kg/m2), * cancer of any type * drug addiction and alcoholism

Keywords: xerostomia diabetes type ii salivary flow antioxidant capacity of saliva aldiamed
dimensional changes of the labial alveolar ridge after socket shield technique with computer guided root sectioning

Conditions: Edentulous Alveolar Ridge; Dental Trauma

Summary: in this study, the dimensional changes of the labial alveolar ridge are digitally assessed after immediate implant placement using the socket shield technique with computer guided sectioning of the root.

ten hopeless teeth in the esthetic zone were included. a computer guide was used to section the root, leaving the coronal 2/3 of its labial part attached to the socket. an implant was then placed. preoperative and postoperative (5 months later) intraoral scans were superimposed with a digital software to assess the dimensional changes of the labial alveolar ridge. linear changes at 1,3 and 5 mm from the gingival margin and mean linear changes in a specified area of interest (aoi) were measured.

Eligibility criteria:
inclusion criteria: * medically healthy patients (asa 1, asa 2 categories) , * over 18 years old presenting with hopeless teeth due to extensive caries, * cervical root fracture, * vertical or oblique root fracture, * multiple failed endodontic treatments, * root resorption. exclusion criteria: * medically compromised patients (the asa 3, asa 4 and asa5 categories) * vertical root fracture involving the labial aspect of the root that will be retained, * horizontal fracture of the root that is too far apically located * presence of acute (active) periapical infection * lack of sufficient bone to obtain implant primary stability apical and/or palatal to the extraction socket, * ankylosed tooth which is positioned too apically in relation to the adjacent teeth, * type 3 extraction sockets according to elian and tarnow extraction sockets classification

Keywords: bone implant interactions periodontology, soft tissue-implant interactions surgical techniques wound healing
bladder cancer screening trial

Conditions: Bladder Cancer; Urothelial Carcinoma; Hematuria; Smoking Cessation

Summary: there is currently no accepted screening strategy for patients at high risk of developing bladder cancer. this study will ask patients to complete a urine test every 6 months for 2 years to help assess if routine screening helps finding bladder cancer at an earlier stage.

bladder cancer is the 4th most common cancer in men and 6th most common cancer overall with over 80,000 new cases in the us per year. the most common causes of bladder cancer are smoking and it is usually found in patients over the age of 50. by the time it is diagnosed, the disease is often advanced since there are few warning signs other than seeing blood in the urine. screening is currently accepted practice for colon, cervical, and breast cancer. however, there is not an accepted screening methodology for bladder cancer. bladder cancer is currently detected in 2-5% of patients who have microhematuria on routine urinalysis, a cheap, non-invasive test obtained by many primary care physicians. bladder cancer diagnosed by microscopic blood on urinalysis is often lower stage than patients diagnosed with visible blood. urine testing, therefore, offers a simple screening mechanism that can be tailored to patients at higher risk for bladder cancer based on age, tobacco exposure and other risk factors. in conjunction with routine traditional urinalysis testing, there are advances in urine molecular markers which utilize protein and genetic alterations resulting in a higher sensitivity and specificity for the detection of bladder cancer. markers have not been evaluated for screening in high-risk populations, and there is a gap in knowledge of the most accurate screening method. early detection of bladder cancer has the potential to identify disease at an earlier stage resulting in a lower burden of treatment, improved quality of life, and improved survival. this study will prospectively screen patients at high risk for the development of bladder cancer at bi-annual intervals with a commonly available urinalysis test that assess for microhematuria and urine based molecular markers. this is a single arm study. the outcomes from the experimental arm will be compared to a historical control (bladder cancer detected by standard of care using seer registries).

Eligibility criteria:
inclusion criteria: * age ≥ 50 * smoking: ≥15 pack-year smoking history * occupation:≥ 15 years of occupational exposures including: textile worker, painter, dry cleaners exclusion criteria: * prior history of bladder, kidney, or prostate cancer * prior evaluation of micro or gross hematuria within the last 2 years * do not provide informed consent
a smart evaluation of an adaptive web-based aud treatment for service members and their partners

Conditions: Alcohol Abuse; Alcohol Use Disorder; Alcohol Drinking; Relations, Interpersonal; Military Family

Summary: the purpose of this study is to evaluate the efficacy of an adaptive web intervention (partners connect) on military spouse drinking behaviors (cps) and service member help-seeking (sms). the investigators want to identify for whom this intervention is most efficacious and on what drinking behaviors and mechanisms. the investigators hypothesize that the intervention will reduce concerned partner drinking and increase service member help-seeking, compared to website resources, and that phone-based craft will increase help-seeking behaviors, compared to those who are guided via a craft workbook.


Eligibility criteria:
inclusion criteria: * at least 18 years of age; * be living together with their partner, with no plans to change that status in the next 2 months; * not be in the military themselves (to reduce concerns about mandated reporting of alcohol use); * score ≥4 on the audit-c for females or ≥5 for males/other; * respond yes to "do you feel safe in your current relationship?" from the partner violence screen; * report not currently being in mental health or alcohol treatment (cp and sm) * understand english fluently, * be willing to try an online program to address risky drinking. we require cohabitating cps and sms with no anticipated changes in the next two months to ensure close contact and opportunity to practice new skills, and those who would feel safe participating. exclusion criteria: * cps in substance use treatment or their sm was in treatment in the last three months; * does not feel safe in the current relationship; * does not understand english fluently; * has an impaired capacity (cognitive, visual, or hearing); * is not cohabitating with their sm

Keywords: military alcohol drinking substance use
impact of umbilical cord clamping time on infant anemia

Conditions: Third Stage of Labor; Healthy; Umbilical Cord Clamping Time; Infant Conditions

Summary: this research was conducted to carry out the effect of umbilical cord clamping time on baby anemia.

this study is an experimental, randomized controlled study. the sample of the study consisted of 65 pregnant women and newborns (intervention=32, control=33) who applied for delivery at ege university medical hospital gynecology and obstetrics clinic at the time of the study. in this study, "descriptive data form of impact of umbilical cord clamping time on infant anemia" was used as a data collection tool. in the intervention group waited 60 seconds for umbilical cord clamping in the second stage of labor, in the control group the umbilical cord was clamped in the first 15 seconds. for the data of the first stage of the study, the neonatal hematocrit and bilirubin measurements and the need for phototherapy due to hyperbilirubinemia were evaluated 48 hours after birth. in the second stage of the study, data on anaemia screening performed in family medicine at the end of the fourth month of birth were examined. statistical analysis of the data from the study was performed using ibm spss statistics 25.0 package program. parametric tests were used for statistical analysis of the data with a normal distribution. the level of statistical significance was determined as p\<0.05.

Eligibility criteria:
inclusion criteria: * apply for normal birth * singleton pregnancy and live fetus * cephalic presentation * estimated birth weight between 2500-4000 grams * birth rates \<5 * women who received iron support during pregnancy * haemoglobin level ≥ 11 gr/dl * no systemic disease or pregnancy complication that may pose a risk for postpartum bleeding. * neonates who don't need for resuscitation after birth * babies who did not receive iron supplements up to the 4th month after birth were included. exclusion criteria: * pregnant women who refuse to participate in the research * neonates who need for resuscitation after birth * babies who receive iron supplements up to the 4th month after birth were excluded.

Keywords: umbilical cord clamping infant anemia midwifery
safety and efficacy of squaric acid dibutyl ester for the treatment of herpes labialis

Conditions: Herpes Labialis

Summary: subjects with a history of recurrent herpes labialis will be sensitized with either 2% sadbe or placebo. following this, subjects sensitized with 2% sadbe will received.2% sqauric acid or.5% squaric acid on their cold sore within 72 hours of a recurrence. subjects sensitized with placebo solution will receive placebo solution on their cold sore within 72 hours of a recurrence. subjects will be followed for up to 6 mos after application of study medication.


Eligibility criteria:
inclusion criteria: * age \>18 * with clinical diagnosis of herpes labialis. * who self report having six or more episodes of herpes labialis in the previous 12 months. exclusion criteria: * pregnant or lactating females. * current or recurrent infection or any underlying condition that may predispose to infection or anyone who has been admitted to the hospital due to bacteremia, pneumonia or any other serious infection. * therapy with glucocorticoid or immunosuppressant at time of recruitment or within past 4 weeks, except for inhaled corticosteroids for asthma. * history of malignancy (except patients with surgically cured basal cell or squamous cell skin cancers who will be eligible) * history of organ transplantation * negative hiv-positive status determined by history at screening or known history of any other immuno-suppressing disease. * severe comorbidities (diabetes mellitus requiring insulin, chf (ef\<50% at baseline will be exclusionary) of any severity, mi, cva or tia within 3 months of screening visit, unstable angina pectoris, oxygen-dependent severe pulmonary disease * subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit. * subjects who have known hypersensitivity to squaric acid or any of its components. * history of recent alcohol or substance abuse (\< 1 year) * any condition judged by the investigator to cause this clinical trial to be detrimental to the patient. * history of psychiatric disease that would interfere with the patient's ability to comply with the study protocol * history of non-compliance with other therapies.
characteristics of patients with neovascular age-related macular degeneration enrolled in the brolucizumab patient support services program

Conditions: Age-related Macular Degeneration (AMD)

Summary: the study was a retrospective, cross-sectional, descriptive study of patients with wet amd who enrolled in the brolucizumab patient support services (pss) program. evidence was generated to describe their baseline demographic and clinical characteristics.

the study was a retrospective, cross-sectional, descriptive study of patients with wet amd who enrolled in the brolucizumab patient support services (pss) program. pss data was obtained from patients with wet amd who enrolled in the program for the index period 10/10/2019 to 04/30/2020. * identification period of the index period: 10/10/2019 to 04/30/2020 * index date: date of enrollment in the pss program * study period: 10/10/2019 to 04/30/2020

Eligibility criteria:
inclusion criteria: * patients were enrolled in the brolucizumab pss program * ≥19 years old exclusion criteria: • none

Keywords: primary plan, amd characteristics, brolucizumab
sacral erector spinae plane block in transurethral prostate resection surgery

Conditions: TURP(Transurethral Resection of Prostate)

Summary: the aim of this study is to investigate the effects of bilateral sacral erector spinae plane block on hemodynamic values, postoperative pain, analgesic use and patient satisfaction during operative period in transurethral prostate resection surgeries under general anesthesia.

the study included patients who were planned to undergo transurethral prostate resection, were informed about the study, and agreed to participate in the study with their written consent, were over 18 years of age, and were in the asa i-ii risk group. those who did not agree to participate in the study, patients under 18 years of age, and those in the asa iii-iv risk group were excluded from the study. patients who agreed to participate in the study were divided into two groups using the sealed envelope method, and general anesthesia was applied to both groups. in the group where the block was to be applied, bilateral sacral erector spinae plane block was performed with local anesthetic (10 ml 0.25% bupivacaine + 5 ml 1% lidocaine) after the 3rd sacral intermedian crest was visualized with preoperative ultrasound. no additional intervention was performed on the patients in the control group other than the surgical procedure and general anesthesia. the hemodynamic values (noninvasive blood pressure, heart rate, peripheral oxygen saturation) of all patients during the operation, total opioid use (remifentanil) during the surgery, and nrs, nausea/vomiting and tramadol amounts at 0, 2, 4, 6, 12, and 24 hours postoperatively were recorded and the values were compared in both groups. thus, it was aimed to evaluate the effects of sacral erector spinae plane block in transurethral prostate resection operations.

Eligibility criteria:
inclusion criteria: * patients who were scheduled for transurethral prostate resection, * who agreed to participate in the study, * who were over 18 years old * asa i-ii risk group exclusion criteria: * patients who did not agree to participate in the study, * those under 18 years old * asa iii-iv risk group

Keywords: bilateral sacral intermedian crest block hemodynamics numerical pain scores quality of recovery-15 (qor-15t)
program for caregivers involved with mental health services

Conditions: Mental Illness

Summary: the purpose of this two-year pilot study is to adapt a 12-week attachment-based parenting intervention for implementation with female adult caregivers who have or are at risk for long-term interpersonal conflict with family members, children, or significant others and are caring for a child between the ages of birth and 7 years.

the purpose of this two-year pilot study is to adapt a 12-week attachment-based parenting intervention (parenting from the inside out or pio) originally developed for substance abusing mothers (as part of an ongoing nida-funded treatment development study; r01 da17294) for implementation with female adult caregivers who have or are at risk for long-term interpersonal conflict with family members, children, or significant others and are caring for a child between the ages of birth and 7 years. the pio intervention involves 12-24 weekly 1 hour individual therapy sessions with masters level therapists who are trained and supervised by dr. suchman (the principal investigator) in the pio approach.

Eligibility criteria:
inclusion criteria: * receive psychiatric services through the adult or young adult treatment team at the west haven mental health clinic * have a child receiving psychiatric services through the child treatment team at the west haven mental health clinic * express interest in receiving a parent intervention at the west haven mental health clinic exclusion criteria: * severe mental health problems (e.g., suicidal, homicidal, psychosis, thought disorder) * severely cognitively impaired * have psychiatric or substance-related symptoms requiring inpatient hospitalization or ambulatory detoxification * are not fluent in english * child has a serious illness or significant developmental delay (e.g., cognitive, language, or motor)

Keywords: parenting mental illness maternal sensitivity parent-child relationship
thoracic epidural for postoperative ileus

Conditions: Ileus

Summary: the investigators try to find whether thoracic epidural analgesia (tea) shortens the first gas-out time compared to iv-pca and promotes earlier discharge after major upper abdominal surgery.

postoperative ileus (poi) is a prolonged inhibition of coordinated bowel activity after surgery. half of patients undergoing major abdominal surgery experience poi making it one of the limiting factors for early recovery. the pathogenesis of poi is multifactorial, and includes neurogenic, inflammatory and pharmacological mechanisms. thoracic epidural analgesia (tea) can induce sympathetic block, attenuate inflammatory reaction and limit use of systemic opioids. in addition, sympatholysis induced by tea can improve microcirculation of bowels and parasympathetic activation can increase gastrointestinal motility. however, studies comparing tea and iv-pca on poi are rare in major upper abdominal surgeries. this study, therefore, compares tea and iv-pca in terms of bowel function recovery as a primary endpoint in major upper abdominal surgeries. secondary endpoints are side effects and hospital stay.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists' (asa) physical statusⅰ-ⅲ exclusion criteria: * asa status of ⅳ, or more * body mass index 30 kg.m2-1 or more * severe renal, hepatic, or neurologic diseases * opioid or systemic analgesic preoperatively

Keywords: thoracic epidural analgesia bowel function recovery
investigation of the effect of nintedanib on the pharmacokinetics of a combination of ethinylestradiol and levonorgestrel in patients with non-small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: investigate the effect of multiple oral doses of nintedanib on the single dose kinetics of a combination of ethinylestradiol and levonorgestrel (microgynon®)

purpose:

Eligibility criteria:
inclusion criteria: * female patients 18 years or older at screening * female patient is postmenopausal or surgically sterilised * patient with locally advanced, metastatic or locally recurrent non-small cell lung cancer with histology of adenocarcinoma * nintedanib (vargatef®) is planned to be prescribed in accordance with the marketing authorisation (smpc) * signed and dated written informed consent in accordance with good clinical practice (gcp) and local legislation prior to admission to the trial exclusion criteria: * any contraindication to nintedanib (vargatef®), ethinylestradiol or levonorgestrel (microgynon®), as specified in the respective labels * use of hormone containing contraceptives (including vaginal and intrauterine devices and including hormone replacement therapy) within 30 days prior to first administration of microgynon® * systemic use of drugs known to induce (e.g. rifampicin, st. john's wort, carbamazepine) or to inhibit (e.g. azole antimycotics, macrolides) cyp3a4 within 7 days prior to first trial drug administration until last pharmacokinetic(pk)-sampling in the trial. exception: allowed is the intake of corticosteroids as docetaxel (pre)medication * history of major thrombotic or clinically relevant major bleeding event in the past 6 months * persistence of clinically relevant therapy related toxicities (i.e. \> common terminology criteria for adverse events \[ctcae\] grade 2) from previous chemotherapy and/or radiotherapy * treatment with other investigational drugs or treatment in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial * gastrointestinal disorders or abnormalities that would interfere with absorption of the trial drugs * major surgery (major according to the investigator's assessment) performed within 4 weeks prior to first treatment within the trial and without complete wound healing * patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial * patients unable to comply with the protocol * previous enrolment in this trial